Epidermal growth factor receptor (EGFR)-targeted therapy by tyrosine kinase inhibitors (TKIs) is the first-line treatment of non-small cell lung cancer (NSCLC).
However, EGFR mutation-mediated TKIs resistance remains a major hurdle for NSCLC treatment.
This study found the opposite roles of calcium (Ca
